a receptor tyrosine kinase of the VEGFR family. Receptor for VEGF, VEGFB and PGF. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. Two splice variant isoforms have been described. Isoform SFlt1 may have an inhibitory role in angiogenesis. Note: This description may include information from UniProtKB.
Protein type: Protein kinase, TK; EC 126.96.36.199; Protein kinase, tyrosine (receptor); Membrane protein, integral; Kinase, protein; EC 188.8.131.52; TK group; VEGFR family
Cellular Component: Golgi apparatus; extracellular space; integral to plasma membrane; cytoplasm; nucleolus; plasma membrane; nucleus; endosome
Molecular Function: vascular endothelial growth factor receptor activity; identical protein binding; protein binding; growth factor binding; transmembrane receptor protein tyrosine kinase activity; ATP binding
Biological Process: regulation of smooth muscle contraction; cell migration; intracellular receptor-mediated signaling pathway; peptidyl-tyrosine phosphorylation; activation of MAPKK activity; protein amino acid autophosphorylation; positive regulation of smooth muscle cell proliferation; positive regulation of phosphoinositide 3-kinase activity; positive regulation of vascular endothelial growth factor receptor signaling pathway; patterning of blood vessels; positive regulation of phosphoinositide 3-kinase cascade; monocyte chemotaxis; positive regulation of MAP kinase activity; positive regulation of angiogenesis; positive regulation of MAPKKK cascade; positive regulation of cell proliferation; response to hypoxia; blood vessel morphogenesis; embryonic morphogenesis; sprouting angiogenesis; cell differentiation; vascular endothelial growth factor receptor signaling pathway; transmembrane receptor protein tyrosine kinase signaling pathway; positive regulation of cell migration
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.